PharmD Summer Research Fellows Study Real-World Safety of a Novel Schizophrenia Treatment
核心洞察
A Binghamton University School of Pharmacy and Pharmaceutical Sciences (搜索) team is evaluating real-world safety of a novel schizophrenia (搜索) therapy using the FDA's Adverse Event Monitoring System (AEMS).
The study addresses a critical evidence gap, as current safety data for the first-in-class therapy is limited to highly controlled clinical trials that may exclude certain patients.
Led by faculty mentors Kenneth "Mac" McCall, Alex Rola, Emily Leppien, and PGY4 resident psychiatrist Gurpreet Singh Guliani, the project involves PharmD students Dev Patel, Vaishvi Gandhi, and Roisin Daly.
A group of PharmD students at Binghamton University's School of Pharmacy and Pharmaceutical Sciences (SOPPS) is investigating the real-world safety of a novel treatment option for schizophrenia (搜索), a complex psychiatric disorder that profoundly impacts daily functioning. The project is hosted by Chair and Clinical Professor of Pharmacy Practice Kenneth "Mac" McCall, Clinical Assistant Professor of Pharmacy Practice Alex Rola, Clinical Associate Professor of Pharmacy Practice Emily Leppien, and PGY4 resident psychiatrist at UHS Hospital (搜索) Gurpreet Singh Guliani, with students Dev Patel, Vaishvi Gandhi, and Roisin Daly leading the research focus.
Although new therapies offer alternatives to traditional dopamine-blocking agents, a significant evidence gap remains, and current safety data is largely limited to highly controlled clinical trials which can exclude certain patients. This research is significant because it addresses the critical need for real-world safety evidence as the medication transitions from restricted trials to broad clinical use.
Leveraging Real-World Pharmacovigilance Data
By utilizing the U.S. Food and Drug Administration (搜索)'s Adverse Event Monitoring System (AEMS), this study evaluates adverse events that may not appear in initial testing, bridging the gap between safety data collected in clinical trials and outcomes observed in psychiatric practice. This provides clinicians and researchers the necessary data to refine monitoring strategies, support prescribing decisions, and improve the safe use of this novel therapy.
For a first-in-class therapy, understanding the timing and context of adverse events in a diverse patient population is essential for ensuring patient safety. The approach directly addresses the limitation that current safety data is confined to highly controlled clinical trials, which can exclude certain patients and therefore may not reflect outcomes in broader clinical use.
A Collaborative Training Environment
This unique opportunity is one of several summer research fellow projects that allow Binghamton students protected, funded time to engage in hands-on research early in their professional training.
"Working with students from different years of the PharmD program creates a collaborative learning environment where they learn with and from one another while developing their research skills," Leppien said. "This is my third summer mentoring student researchers, and each experience has reinforced how valuable these opportunities are for both students and faculty mentors."
Student Motivations and Clinical Significance
The student researchers emphasized the importance of pharmacovigilance for vulnerable patient populations. Dev Patel explained his interest in psychiatric pharmacology, particularly "how novel therapies target specific neural pathways to avoid traditional side effect profiles," and expressed eagerness "to actively contribute to the pharmacovigilance efforts that ensure these advancements remain safe and effective for vulnerable patient groups in everyday practice."
Roisin Daly highlighted the broader clinical need, noting that "individuals struggling with mental health conditions are often stigmatized and face significant barriers to accessing care," and expressed hope to "advocate for this underserved population and improve patient outcomes by contributing to the development and refinement of evidence-based treatment strategies."
Vaishvi Gandhi described a personal motivation rooted in "how prevalent mental health challenges have become today," adding that "witnessing someone close to me struggle with their mental health gave me a personal perspective on the importance of research."
The project underscores the value of real-world safety surveillance in psychiatric pharmacotherapy, providing clinicians and researchers with data to refine monitoring strategies and support prescribing decisions as novel schizophrenia (搜索) therapies move into everyday clinical practice.